Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia— Report of 19 cases
- 25 January 2008
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 23 (2), 228-233
- https://doi.org/10.1002/mds.21809
Abstract
Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT‐A) might also be considered for patients with HSP. We report the effect of BoNT‐A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT‐A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT‐A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT‐A injections in HSP. © 2007 Movement Disorder SocietyKeywords
This publication has 11 references indexed in Scilit:
- The hereditary spastic paraplegiasPublished by Cambridge University Press (CUP) ,2005
- Objective assessment of gait after intrathecal baclofen in hereditary spastic paraplegiaZeitschrift für Neurologie, 2005
- Nerve stimulation boosts botulinum toxin action in spasticityMovement Disorders, 2005
- Gait analysis of sporadic and hereditary spastic paraplegiaZeitschrift für Neurologie, 2004
- USE OF BOTULINUM TOXIN TYPE A IN MANAGEMENT OF ADULT SPASTICITY - A EUROPEAN CONSENSUS STATEMENTJournal of Rehabilitation Medicine, 2003
- Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging studyJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Effect of muscle activity immediately after botulinum toxin injection for writer's crampMovement Disorders, 1999
- Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trialClinical Rehabilitation, 1998
- A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Intrathecal baclofen for spasticity of spinal origin: seven years of experienceJournal of Neurosurgery, 1992